FeesSafety
Pluang+

IREN secures $4B AI capacity contracts, with key milestones ahead for 2026 and 2028 revenue growth.

Market News
17 Sep 2026
Seeking Alpha
View Source
Bullish
IREN secures $4B AI capacity contracts, with key milestones ahead for 2026 and 2028 revenue growth.

IREN Limited has contracted $4 billion in annual recurring revenue (ARR) from AI capacity expected to be operational by 2026, though only $1 billion was active by late August. The company’s initial Horizon 1 phase has been validated, while the success of Horizons 2 through 4 will be critical to meeting December commissioning targets. Customer prepayments cover nearly half of GPU capital expenditure, and equipment financing can fund up to 90% of GPU costs. IREN’s valuation is attractive, trading at about 5.8 times projected 2027 sales and dropping to 2.2 times 2028 revenue as capacity scales, indicating strong growth potential as the AI transition moves from hype to commercial success.

IREN Limited's AI capacity and revenue outlook is presented here as market context. For readers following technology stocks, 133 of 150 US technology-sector stocks on Pluang rose while 14 fell. Notable movers include GLW at USD 148.31 with a 2.83% increase, TER at USD 350.55 up 2.76%, and UMC at USD 23.15 rising 2.75%. This data is as of Sep 17, 2026 17:41 WIB.

More News

Canada's Royal Canadian Legion launches 2026 Poppy Campaign with new contactless donations and a commemorative mural.

Canada's Royal Canadian Legion launches 2026 Poppy Campaign with new contactless donations and a commemorative mural.

The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...

Others
Bullish
3 hours ago
XBiotech appoints Jan-Paul Simard as Co-CEO alongside Sushma Shivaswamy to strengthen leadership.

XBiotech appoints Jan-Paul Simard as Co-CEO alongside Sushma Shivaswamy to strengthen leadership.

XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...

Market News
Bullish
4 hours ago
XBiotech appoints Sushma Shivaswamy and Jan-Paul Simard as co-CEOs to lead antibody therapy development.

XBiotech appoints Sushma Shivaswamy and Jan-Paul Simard as co-CEOs to lead antibody therapy development.

XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...

Market News
Bullish
4 hours ago
Wallet linked to BitMEX co-founder moves $19M in Ether to Binance, Galaxy Digital, and FalconX

Wallet linked to BitMEX co-founder moves $19M in Ether to Binance, Galaxy Digital, and FalconX

A wallet associated with BitMEX co-founder Arthur Hayes transferred 8,000 Ether (ETH) on October 24, valued at about $19 million at the time. The ETH was split evenly among Binance, Galaxy Digital, and FalconX, each receiving 1,600 ETH worth approxim...

Technical Signals
Neutral
4 hours ago
Starknet's DeFi TVL drops 74% as Extended moves settlement to Circle's Arc

Starknet's DeFi TVL drops 74% as Extended moves settlement to Circle's Arc

Starknet's total value locked (TVL) in decentralized finance fell 73.8% from $157.76 million on Oct. 21 to $41.39 million on Oct. 24, following Extended's settlement migration to Circle's Arc on Oct. 22. The stablecoin market cap also dropped about 7...

Protocol Fundamentals
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App